LONDON–(BUSINESS WIRE)–#Biotechnology–The global polycystic kidney disease drugs market is expected to post a
CAGR of more than 6% during the period 2019-2023, according to the
latest market research report by Technavio.
A key factor driving the growth of the global polycystic kidney disease
drugs market size is the special regulatory designations. Polycystic
kidney disease is a devastating and rare autosomal kidney disorder, and
if left untreated, it may be life-threatening. As the market has only
one approved drug for curative treatment of the disease,
under-development drugs are receiving special regulatory designations
such as fast track designation and orphan drug designation. For
instance, venglustat, a therapeutic candidate under development for the
treatment of ADPKD received orphan drug designation from the US FDA.
Such special regulatory designations make the drug approval and launch
procedures easy, which will drive the polycystic kidney disease drugs
market growth during the forecast period.
As per Technavio, favorable reimbursement policies will have a positive
impact on the market and contribute to its growth significantly over the
forecast period. This global
polycystic kidney disease drugs market 2019-2023 research
report also analyzes other important trends and market drivers that will
affect market growth over 2019-2023.
Global polycystic kidney disease drugs market:
Favorable reimbursement policies
Off-label therapies such as NSAIDs and antibiotics lisinopril,
benazepril, enalapril, captopril, and codeine are most commonly used for
the symptomatic treatment of polycystic kidney disease. Moreover, the
market has witnessed the approval of a novel drug for the curative
treatment of the condition. However, the high cost of this drug remains
a challenge for patients and the healthcare system. To overcome this
challenge, several government and non-government organizations are
focusing on providing financial assistance and clinical assistance for
the treatment of various kidney diseases, including chronic conditions
such as polycystic kidney disease. These policies help patients adhere
to the treatment regimen, even if it goes into a long-term tenure. Such
favorable reimbursement policies will fuel the growth of the polycystic
kidney disease drugs market.
“Apart from the favorable reimbursement policies, other factors such
as growing awareness about kidney diseases, investments in R&D, and the
increase in research funding will have a significant impact on the
growth of the polycystic kidney disease drugs market size during the
forecast period,” says a senior analyst at Technavio.
Global polycystic kidney disease drugs market:
Segmentation analysis
This market research report segments the global polycystic kidney
disease drugs market by type (ADPKD, and ARPKD), and geographic regions
(North America, Europe, Asia, and ROW).
The North American region led the polycystic kidney disease drugs market
in 2018, followed by Europe, Asia, and ROW respectively. The growth of
the polycystic kidney disease drugs market in North America can be
attributed to factors such as the increase in cases of polycystic kidney
disease, rising awareness about the disease and available treatment
options, increasing number of support programs conducted by vendors and
various organizations, and the advances in research activities of
polycystic kidney disease.
Looking for more information on this market? Request
a free sample report
Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.
Some of the key topics covered in the report include:
Market Landscape
- Market ecosystem
- Market characteristics
- Market segmentation analysis
Market Sizing
- Market definition
- Market size and forecast
Five Forces Analysis
Market Segmentation
Geographical Segmentation
- Regional comparison
- Key leading countries
Market Drivers
Market Challenges
Market Trends
Vendor Landscape
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Competitive scenario
About Technavio
Technavio
is a leading global technology research and advisory company.
Their research and analysis focuses on emerging market trends and
provides actionable insights to help businesses identify market
opportunities and develop effective strategies to optimize their market
positions.
With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team
at media@technavio.com.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com